Pharmacotherapeutics for osteoporosis prevention and treatment

Journal of Midwifery and Women's Health

Volumn 48, Issue 1, 2003, Pages 39-52

  Davidson, Michele R ^a,b  

^a College of Nursing/Health Science ^*  (United States)

^b GEORGE MASON UNIVERSITY   (United States)

Author keywords

Biphosphonates; Osteoporosis; Postmenopausal; Selective estrogen receptor modulators

Indexed keywords

'POSTURE'; ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM; CALCIUM CARBONATE; CALCIUM GLUBIONATE; CALCIUM PHOSPHATE; CALCIUM PHOSPHATE DIBASIC; CITRATE CALCIUM; CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; COUMARIN; DIAZEPAM; DIAZOXIDE; ESTROGEN; ETIDRONIC ACID; FLUORIDE SODIUM; GLUCOCORTICOID; GLUCONATE CALCIUM; KALCINATE; MEDROXYPROGESTERONE ACETATE; PAMIDRONIC ACID; PHENYTOIN; RALOXIFENE; RISEDRONIC ACID; SALCATONIN; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN CITRATE; TILUDRONIC ACID; TUMS; UNINDEXED DRUG; VITAMIN D; WARFARIN; ZOLEDRONIC ACID;

ABDOMINAL PAIN; AGING; ARTICLE; BACKACHE; BODY HEIGHT; BONE DENSITY; BONE DISEASE; BONE PAIN; BREAST CANCER; CAUCASIAN; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DEPRESSION; DIET SUPPLEMENTATION; DIET THERAPY; DISEASE COURSE; DRUG ANTAGONISM; DRUG ERUPTION; DUAL ENERGY X RAY ABSORPTIOMETRY; ESOPHAGUS DISEASE; EXERCISE; FAMILY HISTORY; FEMALE; FLUSHING; FRAGILITY FRACTURE; GASTROINTESTINAL DISEASE; GYNECOLOGY; HEARTBURN; HORMONAL THERAPY; HUMAN; HYPERCALCEMIA; HYPERCALCIURIA; ISCHEMIC HEART DISEASE; KYPHOSIS; LEG CRAMP; LIFESTYLE; LUNG EMBOLISM; MATERNAL CARE; MEDICAL DECISION MAKING; MIDWIFE; MYALGIA; NAUSEA; NOSE DISEASE; OSTEOPOROSIS; PATHOPHYSIOLOGY; PATIENT CARE; PATIENT COUNSELING; PATIENT EDUCATION; PHOTON ABSORPTIOMETRY; PHYSICAL EXAMINATION; POSTMENOPAUSE; PRIORITY JOURNAL; PROTEIN INTAKE; PSYCHOSOCIAL WITHDRAWAL; RACE DIFFERENCE; RESPIRATORY TRACT DISEASE; RHINITIS; RISK ASSESSMENT; RISK FACTOR; SCREENING TEST; SIDE EFFECT; STROKE; SYMPTOM; THROMBOEMBOLISM; UNITED STATES; X RAY SPECTROMETRY; AGE; ANAMNESIS; CLINICAL TRIAL; DRUG EFFECT; ESTROGEN THERAPY; MALE; RADIODENSITOMETRY; TREATMENT OUTCOME;

AGE FACTORS; BONE DENSITY; CALCITONIN; CLINICAL TRIALS; DENSITOMETRY, X-RAY; DIPHOSPHONATES; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; LIFE STYLE; MALE; MEDICAL HISTORY TAKING; OSTEOPOROSIS; RISK FACTORS; SELECTIVE ESTROGEN RECEPTOR MODULATORS; SODIUM FLUORIDE; TREATMENT OUTCOME; UNITED STATES;

EID: 0037264794     PISSN: 15269523     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1526-9523(02)00359-8     Document Type: Article

References (49)

1. National Institutes of Health http://www.osteo.org/osteofastfact.html Osteoporosis and Related Bone Diseases National Resource Center. Fast facts on osteoporosis. [Internet 2002 cited January 4, 2002
2. Greene W.B. (Ed.), Essentials of musculoskeletal care 2nd ed 2001 American Academy of Orthopedic Surgeons Rosemont (IL)
3. American Medical Association Managing osteoporosis: update in patient management 2001 American Medical AssociationWashington (DC) October, 2001
4. National Osteoporosis Foundation Physician's guide to the prevention and treatment of osteoporosis 1998 National Osteoporosis Foundation Washington (DC)
5. Insel P. Turner R.E. Ross D. Nutrition: 2002 update 2002 Jones - Bartlett Publishers Sudbury (MA)
6. Chin H.G. On call obstetrics and gynecology 2nd ed 2001 W.B. Saunders CompanyPhiladelphia
7. Davidson M. DeSimone M.E. Confronting osteoporosis: what we know, where we're headed Clin Rev 12 2002 76-82
8. Cauley J.A. Black D.M. Barrett-Connor E. Effects of hormone replacement therapy on clinical fractures and height loss. The heart and estrogen/progestin replacement study (HERS) Am J Med 110 2001 442-450
9. Writing Group for the Women's Health Initiative Investigators Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial J. Am Med Assoc 288 2002 321-333
10. Johnson B.E. Johnson C.A. Murray J.L. Apgar B.S. Women's health care handbook 2nd ed 2000 Hanley and Belfus Inc Philadelphia (PA)
11. Michaelsson K. Baron J.A. Farahmand B.Y. Ljunghall S. Influence of parity and lactation on hip fracture risk Am J Epidemiol 153 2001 1166-1172
12. Karlsson C. Obrant K.J. Karlsson M. Pregnancy and lactation confer reversible bone loss in humans Osteoporosis Int 12 2001 828-834
13. Jones G. Scott F. Low bone mass in premenopausal parous women: identification and the effect of an information and bone density feedback program J Clin Densitom 2 1999 109-115
14. Henderson P.H. Sowers M. Kutzko K.E. Jannausch M.L. Bone mineral density in grand multiparous women with extended lactation Am J Obstet Gynecol 182 2000 1371-1377
15. Grossman J.M. MacLean C.H. Quality indicators for the management of osteoporosis in vulnerable elders Ann Intern Med 135 Part 2 Suppl 2001 722-730
16. Skolnick A.A. "Female athletic triad" risk for women J Am Med Assoc 270 1993 921-923
17. Sachs M.I. Risk factors associated with glucocorticoid-induced adverse effects in children with severe asthma Pediatrics 108 Suppl 2001 564-565
18. Clowes J.A. Peel N. Eastell R. Glucocorticoid-induced osteoporosis Curr Opin Rheumatol 13 2001 326-332
19. Cahill B.C. O'Rourke M.K. Parker S. Prevention of bone loss and fracture after lung transplantation: a pilot study Transplantation 72 2001 1251-1255
20. Bahamondes L. Perrotti M. Castro S. Faundes D. Petta C. Bedone A. Forearm bone density in users of Depo-Provera as a contraceptive method Fertil Steril 71 1999 849-852
21. Perrotti M. Bahamondes L.G. Petta C. Castro S. Forearm bone density in long-term users of oral combined contraceptives and depot medroxyprogesterone acetate Fertil Steril 76 2001 469-473
22. Cromer B.A. Effects of hormonal contraceptives on bone mineral density Drug Saf 20 1999 213-222
23. Bickley L.S. Hoekelman R.A. Bates B. Bates' guide to physical examination and history taking 7th ed 1999 Lippincott, Williams - WilkinsPhiladelphia (PA)
24. Cadarette S.M. Jaglal S.B. Murray T.M. McIsaac W.J. Joseph L. Brown J.P. Evaluation of decision rules for referring women for bone densitometry by dual-energy x-ray absorptiometry J Am Med Assoc 286 2001 57-63
25. Blake G.M. Fogelman I. Applications of bone mineral densitometry for osteoporosis Endocrinol Metab Clin North Am 27 1998 267-285
26. World Health Organization (WHO) Study Group Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: report of a WHO Study Group. WHO Technical Report Series 843 1994 1-129 WHO Geneva, Switzerland
27. North American Menopause Society Management of postmenopausal osteoporosis: position statement of the North American Menopause Society Menopause 9 2002 84-101
28. Kannus P. Preventing osteoporosis, falls, and fractures among elderly people. Promotion of lifelong physical activity is essential BMJ 318 1999 205-206
29. Hagberg J.M. Zmuda J.M. McCole S.D. Rodgers K.S. Ferrell R.E. Wilund K.R. et al. Moderate physical activity is associated with higher bone mineral density in postmenopausal women J Am Geriatr Soc 49 2001 1411-1417
30. Abrams A.C. Clinical drug therapy: rationales for nursing practice 6th ed 2001 Lippincott, Williams, - WilkinsPhiladelphia (PA)
31. American College of Rheumatology Task Force on Osteoporosis Guidelines Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis Arthritis Rheum 39 1996 1791-1801
32. Homik J, Suarez-Almazor ME, Shea B. Calcium and vitamin D for corticosteroid-induced osteoporosis. Cochrane Database Syst Rev 2000;CD000952. Oxford
33. Promislow J.H. Goodman-Gruen D. Slymen D.J. Protein consumption and bone mineral density in the elderly: the Rancho Bernardo study Am J Epidemiol 155 2002 636-644
34. Dawson-Hughes B. Harris S.S. Calcium intake influences the association of protein intake with rates of bone loss in elderly men and women Am J Clin Nutr 75 2002 609-610
35. Standing Committee on the Scientific Evaluation of Dietary Reference Intakes Food and Nutrition Board, Institute of Medicine. Dietary reference intakes for calcium, phonsporus, magnesium, vitamin D and fluoride 1997 National Academy PressWashington (DC)
36. Haguenauer D, Welch V, Shea B, Tugwell P, Wells G. Fluoride for treating postmenopausal osteoporosis (Cochrane Review). In: The Cochrane Library, Issue 3, 2002. Oxford: Update software
37. American College of Obstetricians and Gynecologists News Release. Statement on results of the HERSII trial on hormone replacement therapy [Internet] [cited August 6, 2002]. Available from www.acog.org/fromme/publications/pressleases/nr07-02-02.cfm
38. Schnitzer T. Bone H.G. Crepaldi G. Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis Aging Clin Exp Res 12 2000 1-12
39. Lobo R.A. Zacur H.Z. Caubel P. Lane R. A novel intermittent regimen of norgestimate to preserve the beneficial effects of 17 b-estradiol on lipid and lipoprotein profiles Am J Obstet Gynecol 182 2000 41-49
40. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group Harris S.T. Watts N.B. Genant H.K. McKeever C.D. Hangartner T. et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial J Am Med Assoc 282 1999 1344-1352
41. Levinson W. Altkorn D. Primary prevention of postmenopausal osteoporosis J Am Med Assoc 280 1998 1821-1832
42. Chrischilles E.A. Dasbach E.J. Rubenstein L.M. Cook J.R. Tabor H.K. Black D.M. Fracture Intervention Trial Research Group. The effect of alendronate on fracture-related healthcare utilization and costs: the fracture intervention trial Osteoporosis Int 12 2001 654-660
43. Levis S. Quandt S.A. Thompson D. Scott J. Schneider D.L. Ross P.D. et al. Alendronate reduces the risk of multiple symptomatic fractures: results from the fracture intervention study J Am Geriatr Soc 50 2002 409-415
44. Cranney A, Welch V, Adachi JD, Homik J, Shea B, Suarez-Almazor ME, et al. Calcitonin for preventing and treating corticosteroid-induced osteoporosis (Cochrane Review). In: The Cochrane Library, Issue 3, 2002. Oxford: Update software
45. Johnell O. Scheele W.H. Reginster J.Y. Need A.G. Seeman E. Additive effects of raloxifene and alendronate on bone density and biochemical markers of bone remodeling in postmenopausal women with osteoporosis J Clin Endocrinol Metab 87 2002 985-992
46. Hosking D. Chilvers C.E. Christiansen C. Ravn P. Wasnich R. Ross P. et al. Prevention of bone loss with alendronate in postmenopausal women under 60 years of age N Engl J Med 338 1998 485-492
47. Reid I.R. Brown J.P. Burckhardt P. Horowitz Z. Richardson P. Trechsel U. Intravenous zoledronic acid in postmenopausal women with low bone mineral density N Engl J Med 346 2002 653
48. Kostenuik P.J. Capparelli C. Morony S. Adamu S. Shimamoto G. Shen V. et al. OPG and PTH-(1-34) have additive effects on bone density and mechanical strength in osteopenic ovariectomized rats Endocrinology 142 2001 4295-4304
49. Viereck V. Grundker C. Blaschke S. Phytoestrogen genistein stimulates the production of osteoprotegerin by human trabecular osteoclasts J Cell Biochem 84 2002 725-735